Shanghai Henlius Biotech (FRA:2E8) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2E8 Shanghai Henlius Biotech Inc FRA:2E8
50 GF Score
Price €7.30
GF Value €3.38
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Shanghai Henlius Biotech Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:2E8
50GF Score
Shanghai Henlius Biotech Inc FRA:2E8
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shanghai Henlius Biotech (FRA:2E8) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Henlius Biotech stock appears to be overvalued. The current stock price of €7.30 is trading 116% above its estimated GF Value™ of €3.38. GuruFocus considers Shanghai Henlius Biotech to be Significantly Overvalued.

Key valuation signals for FRA:2E8:

  • Dividends Received:
  • GF Value™: €3.38 vs. price of €7.30 (116% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the FRA:2E8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Henlius Biotech Business Description

Other Exchanges 02696:Hong Kong
Address B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
50GF Score

Get the complete analysis for FRA:2E8

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.30
Price
€3.38
GF Value